Clinical Trials Logo

Pancreatic Neuroendocrine Tumors clinical trials

View clinical trials related to Pancreatic Neuroendocrine Tumors.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02110563 Terminated - Multiple Myeloma Clinical Trials

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

Start date: April 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene MYC. MYC oncogene activation is important to the growth of many hematologic and solid tumor malignancies. In this study the Sponsor proposes to study DCR-MYC and its ability to inhibit MYC and thereby inhibit cancer cell growth.

NCT ID: NCT01648465 Terminated - Clinical trials for Pancreatic Neuroendocrine Tumors

Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors

Start date: August 6, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the efficacy and safety of everolimus administered as a first-line treatment in newly-diagnosed patients with advanced or inoperable Gastrointestinal (GI) or pancreatic neuroendocrine tumors.

NCT ID: NCT00947167 Terminated - Neuroblastoma Clinical Trials

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Start date: March 2009
Phase: Phase 2
Study type: Interventional

To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who have stable disease or progressive disease at three months (Simon design).